Summary
Radioligand therapy is quickly establishing itself as a transformative force in oncology, with demand accelerating so rapidly that manufacturers are under pressure to scale up production.
Among the leaders, Novartis is advancing its late-stage candidate 225Ac-PSMA-617, while a growing competitive landscape is taking shape.
Companies such as Curium Pharma (177Lu-PSMA-I&T), ITM Isotope Technologies (ITM-11), Fusion Pharmaceuticals (FPI-2265), and Clarity Pharmaceuticals (67Cu-SAR-bisPSMA) are progressing promising assets through mid- to late-stage development.
Key players, including Bayer, ARTBIO, Convergent Therapeutics, Perspective Therapeutic...
